<SEC-DOCUMENT>0001628280-21-016443.txt : 20210810
<SEC-HEADER>0001628280-21-016443.hdr.sgml : 20210810
<ACCEPTANCE-DATETIME>20210810171551
ACCESSION NUMBER:		0001628280-21-016443
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210810
ITEM INFORMATION:		Results of Operations and Financial Condition
FILED AS OF DATE:		20210810
DATE AS OF CHANGE:		20210810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		211161037

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a2021q28k-er.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8689d192f5ec4c069742f9dab70efc72_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WASHINGTON, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________________________</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FORM 8-K</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________________________</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(D)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:51.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of Report (Date of Earliest Event Reported)&#58;  August 10, 2021 (August 10, 2021)</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)     </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:37.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.935%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Tennessee</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">001-33637</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">62-1765329</font></td></tr><tr style="height:6pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</font></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</font></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</font></td></tr><tr style="height:11pt"><td colspan="9" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2525 West End Avenue, Suite 950, Nashville, Tennessee 37203</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices) (Zip Code)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(615) 255-0068</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Former name or former address, if changed since last report)</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act&#58;</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:32.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of exchanged on which registered</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, no par value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CPIX</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Global Select Market</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter).</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 &#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 10, 2021, Cumberland Pharmaceuticals Inc. (the &#34;Company&#34;) issued a press release which provided a company update and the financial results for the three months and six months ended June 30, 2021.  A copy of the press release is attached as </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="a2021q2-ex991er.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.1</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.</font></div><div style="margin-top:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#34;Exchange Act&#34;), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Item 9.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Financial Statements and Exhibits</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(d)  Exhibits</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.461%"><tr><td style="width:1.0%"></td><td style="width:18.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="a2021q2-ex991er.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">99.1</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="a2021q2-ex991er.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Press release dated August 10, 2021</a></font></div></td></tr></table></div><div style="margin-top:11.25pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.25pt"><font><br></font></div><div style="margin-top:11.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-top:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; August 11, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:11.25pt;text-align:right"><font><br></font></div><div style="margin-top:11.25pt;text-align:right"><font><br></font></div><div style="margin-top:11.25pt;text-align:right"><font><br></font></div><div style="margin-top:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:11.25pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2021q2-ex991er.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9323e3cb16af48458579f69c6a9eb28a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><img alt="cumberlandpharmaimageaa06.jpg" src="cumberlandpharmaimageaa06.jpg" style="height:92px;margin-bottom:5pt;vertical-align:text-bottom;width:408px"></div><div style="margin-bottom:6pt;margin-top:21pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS REPORTS </font></div><div style="margin-bottom:21pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> SECOND QUARTER 2021 FINANCIAL RESULTS &#38; COMPANY UPDATE</font></div><div style="margin-bottom:21pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Year-to-date net revenues up 9.3%</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NASHVILLE, Tennessee (Tuesday, August 10, 2021) - Cumberland Pharmaceuticals Inc. (NASDAQ&#58; CPIX)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a specialty pharmaceutical company, today is providing a company update and second quarter 2021 financial results. Net revenues from continuing operations during the quarter were $9.1 million and totaled $19.6 million for the first half of 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The company also recorded an additional $500,000 in revenue during the second quarter and $1 million year to date, associated with divested product rights for two brands it is no longer distributing.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">While there was a slight decline in revenues during the second quarter 2021 compared to the prior year period, net revenues for the first half of 2021 were up 9.3% compared to the same period in 2020. The Company also posted year to date net income of $1.4 million during the first half of 2021, compared to a loss of $2 million during the prior year period. </font></div><div style="margin-bottom:9pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company's financial position included $89 million in total assets, with $26 million in cash, $41 million of total liabilities, and $48 million of shareholders&#8217; equity at the end of the quarter.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Cumberland continued to face headwinds due to the pandemic, but we are fortunate to have a diversified product portfolio that helped us counter the negative effects on our business,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;We have adjusted our strategies and reinvented the way we operate in order to support our customers and the patients who can benefit from the delivery of our medicines.&#8221;</font></div><div style="margin-bottom:9pt;margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECENT COMPANY DEVELOPMENTS&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ESG Report</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In July 2021, Cumberland released its second annual </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Sustainability Report </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#34;ESG Report&#34;), which details the Company&#8217;s activities pertaining to environmental, social and governance (&#8220;ESG&#8221;) matters. After issuing an inaugural ESG report last year, the Company remains committed to sustainability and to maintaining transparency of its corporate operations. As the largest biopharmaceutical company founded and headquartered in the Mid-South, Cumberland holds itself to the highest standards of ethical practices and understands the importance of recognizing and addressing the Company&#8217;s impact on its constituents, the community and the environment.</font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The ESG Report notes that in 2020, Cumberland provided nearly 2.5 million patient doses of its products, safely disposed of over 4,000 pounds of expired and damaged products and had no product recalls. The Company also had no brands that were listed on the U.S. Food and Drug Administration's (&#34;FDA&#34;) MedWatch Safety Alerts for Human Medical Products, no brand issues that were identified by the FDA from their Adverse Event Reporting System and no clinical trials that were terminated due to failure to practice good clinical standards.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The ESG Report also highlights several initiatives Cumberland implemented as part of its commitment to delivering high-quality pharmaceutical products to improve patient care. For example, the Company continued a program to serialize all commercial products sold in the United States, allowing it to track every unit distributed, which helps to prevent counterfeit drugs from entering the market under the Cumberland brand. In addition, through its coupon program, Cumberland covers up to 90% of patient prescription costs for the Company&#8217;s gastrointestinal products.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The ESG Report also highlights Cumberland&#8217;s investment in its employees through continuing education programs, employee development initiatives and employee recognition awards. Cumberland&#8217;s workforce is 46% women &#8211; and 18% of the Company&#8217;s employees are minorities.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Case Studies</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In June 2021, Cumberland released a series of case reports describing the effectiveness of Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">telavancin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) in treating secondary bacterial infections in COVID-19 patients &#8211; particularly those with other significant health problems, such as obesity, diabetes and heart disease. Cumberland&#8217;s Vibativ product has been used across the country to help COVID-19 patients who develop secondary bacterial infections in their lungs. Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia that can result from COVID-19, flu and other infections. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company compiled a dossier of patient case studies from across the country outlining several real-world instances where Vibativ effectively and safely treated the hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia resulting from MSSA and MRSA infections that developed in patients hospitalized with COVID-19.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Hyponatremia Publication in Support of Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In late 2020, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Health Outcome Predictive Evaluation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (HOPE) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Registry Analysis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, an international study of over 4,000 patients, found that patients hospitalized with COVID-19 had a high risk of developing hyponatremia. These COVID-19 patients also had a higher incidence of mortality due to their hyponatremia. The study results support the use of an intravenous vaptan to treat hyponatremia in critically ill patients afflicted with COVID-19. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. Cumberland&#8217;s Vaprisol product is one of two branded prescription products indicated for the treatment of hyponatremia, and the only intravenously administered branded treatment.  Vaprisol has a proven day one response to help normalize serum sodium levels in hyponatremic patients and move them out of the ICU as efficiently as possible. </font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Chief Financial Officer Appointment</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On May 17, 2021, Cumberland appointed John Hamm as its new Senior Director Finance &#38; Accounting and Chief Financial Officer. In this role, his responsibilities include management of all the Company&#8217;s finance and accounting activities, while he continues to oversee corporate development and legal matters. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. Hamm has more than 25 years of finance and accounting experience, including 20 years in health care. He previously held the positions of Chief Operating Officer and Chief Financial Officer, Pharmacy at HealthSpring, Inc., a managed care organization now operating as Cigna-HealthSpring. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">He was also the Vice President Finance at Emdeon Business Services. Emdeon Inc., a healthcare technology firm that now operates as Change Healthcare Inc., a NASDAQ listed company with over $3 billion in annual revenues.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mr. Hamm holds a Bachelor of Science in Business Administration with a minor in Accounting from Wheeling University. He earned his Master&#8217;s in Business Administration with an emphasis in Accounting from West Virginia University.  He is a Certified Management Accountant (CMA) and Certified Financial Manager (CFM).</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prior to this new appointment, Mr. Hamm served as Cumberland&#8217;s Director Corporate Development. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Paycheck Protection Program</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), which was enacted March 27, 2020. The PPP is administered by the U.S. Small Business Administration (&#8220;SBA&#8221;). </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the PPP requirements, loan funds were used to maintain payroll, continue group health care benefits, and pay for rent and utilities during the pandemic. Cumberland applied for this loan after carefully considering, with Pinnacle Bank, the eligibility criteria to participate in this program, and determining that it met those criteria. The Company evaluated and provided information on its payroll and other qualifying expenses to determine the amount of PPP funds to apply for. Due to assistance from the PPP loan, the Company did not lay off or furlough any employees as a result of the COVID-19 pandemic.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. Cumberland used the PPP loan funds for such qualifying expenses. In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness and on June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RediTrex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Launch</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During late 2018, Cumberland completed the submission of and filed with the FDA a New Drug Application for its RediTrex methotrexate injection product. RediTrex is a new line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In December 2019, the Company received FDA approval for RediTrex and began planning for the launch of the product line. Cumberland provided initial shipments of RediTrex to accounts in November 2020 and is planning to launch the product line nationally in late September 2021. </font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ifetroban Phase II Studies</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland is sponsoring Phase II clinical programs to evaluate its ifetroban product candidates in 1) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, a rare, fatal, genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles, 2) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 3) Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, the Company has completed two pilot Phase II studies involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure and 2) patients with Portal Hypertension that is associated with chronic liver disease.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additional pilot preclinical and clinical studies of ifetroban are underway, including several investigator-initiated trials. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Enrollment in these clinical studies was interrupted due to the COVID-19 pandemic. While enrollment of new patients has been limited in 2021, many of the clinical study sites have reopened and resumed screening of patients for potential enrollment into the studies. Cumberland is awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, the Company&#8217;s first new chemical entity.</font></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FINANCIAL RESULTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58; </font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Revenues&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the three months ended June 30, 2021, net revenues from ongoing operations were $9.1 million, compared to $9.6 million for the prior year period. The company also recorded an additional $500,000 in revenue during the second quarter associated with divested rights to products that the company no longer distributes.</font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net revenue by product for the second quarter 2021, included $5.3 million for Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,  $1.8 million for Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> ,  $0.9 million for Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and $0.4 million for Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Year-to-date 2021 net revenues were $19.6 million, compared to $17.9 million during the first half of 2020. There were additional revenues of $1.0 million during the first six months of 2021 associated with the divested product rights.</font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Year-to-date 2021 net revenues by product were $8.3 million for Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, $6.9 million for Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, $2.5 million for Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and $1.5 million for Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operating Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Total operating expenses for the three months ended June 30, 2021, were $10.5 million, compared to $11.2 million during the prior year period. </font></div><div style="margin-top:8pt;padding-right:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Earnings&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Net income for the second quarter 2021 was $1.2 million or $0.08 a share, compared to a loss of $0.9 million or $0.06 a share for the prior year period.  The adjusted loss for the second quarter was $16,000, compared to an adjusted loss of $120,000 for the prior year period. </font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Year-to-date net income in 2021 was $1.4 million, compared to a loss of $2 million during the first six months of 2020. Adjusted earnings for the first half of 2021 were $1 million, compared to an adjusted loss of $0.5 million during the same period in 2020.</font></div><div style="margin-top:8pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Balance Sheet&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  At June 30, 2021, Cumberland had $88.9 million in total assets including $25.7 million in cash and cash equivalents. Total liabilities were $41.0 million, including $14.0 million outstanding on the Company's revolving line of credit, resulting in total shareholders' equity of $48.0 million.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-right:4.5pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9323e3cb16af48458579f69c6a9eb28a_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CONFERENCE CALL &#38; WEBCAST&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A conference call and live internet webcast will be held on Tuesday, August&#160;10, at 4&#58;30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers).  The Conference ID for the rebroadcast is 3985462. The live webcast and rebroadcast can be accessed via Cumberland&#8217;s website at https&#58;&#47;&#47;investor.cumberlandpharma.com&#47;events-calendar.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ABOUT CUMBERLAND PHARMACEUTICALS&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cumberland Pharmaceuticals Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is a specialty pharmaceutical company focused on the delivery of branded prescription products to improve patient care. The Company develops, acquires and commercializes brands for the hospital acute care, gastroenterology and rheumatoid arthritis markets.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company&#8217;s portfolio of FDA-approved brands includes&#58;</font></div><div style="margin-top:8pt;padding-left:31.5pt;padding-right:20.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Injection, for the treatment of acetaminophen poisoning&#59;</font></div><div style="margin-top:8pt;padding-left:31.5pt;padding-right:20.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Injection, for the treatment of pain and fever&#59;</font></div><div style="margin-top:8pt;padding-left:31.5pt;padding-right:20.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">lactulose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) for Oral Solution, a prescription laxative, for the treatment of constipation&#59;</font></div><div style="margin-top:8pt;padding-left:31.5pt;padding-right:20.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-Pak</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) for the treatment of Helicobacter pylori (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease&#59;</font></div><div style="margin-top:8pt;padding-left:31.5pt;padding-right:20.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.5pt">RediTrex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(methotrexate)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis&#59;</font></div><div style="margin-top:8pt;padding-left:31.5pt;padding-right:20.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia&#59; and</font></div><div style="margin-top:8pt;padding-left:31.5pt;padding-right:20.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">telavancin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections&#59;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company also has Phase II clinical programs underway evaluating its product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis, and Aspirin-Exacerbated Respiratory Disease.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the Company&#8217;s website </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.cumberlandpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (ibuprofen) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever.  It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.caldolor.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (lactulose) Oral Solution</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.kristalose.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (telavancin) for Injection</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information please visit </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.vibativ.com.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About RediTrex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (methotrexate) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RediTrex is a single-dose prefilled syringe containing prescription methotrexate. RediTrex is used to treat adults with severe, active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis, after treatment with other medicines including non-steroidal anti-inflammatory drugs (NSAIDS) have been used and did not work well. Methotrexate can control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have failed. For full prescribing and safety information, visit </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.reditrex.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (conivaptan hydrochloride) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal.  This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia.  The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.vaprisol.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Omeclamox</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">-Pak (omeprazole, clarithromycin, amoxicillin)</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces. Clarithromycin and amoxicillin are antibacterial drugs, which inhibit the growth of bacteria allowing the stomach lining to heal. Omeclamox-Pak is contraindicated in patients with a history of hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. For full prescribing and safety information, visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.omeclamox.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Acetadote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> (acetylcysteine) Injection</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. For full prescribing and safety information, visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.acetadote.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Cumberland Emerging Technologies (CET)</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland Emerging Technologies, Inc. (</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.cet-fund.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN, and WinHealth. The mission of CET is to advance biomedical technologies and products conceived at Vanderbilt University and other regional research centers towards the marketplace.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center provides laboratory space, equipment and infrastructure for CET&#8217;s activities and other early-stage life sciences ventures.</font></div><div id="i9323e3cb16af48458579f69c6a9eb28a_7"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">FORWARD LOOKING STATEMENTS&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SOURCE&#58; Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investor Contact&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Media Contacts&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shayla Simpson</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molly Aggas</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bailee Mulder</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dalton Agency</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dalton Agency</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615) 255-0068</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704) 641-6641</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615) 515-4885</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- MORE -</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21pt;font-weight:700;line-height:120%">FINANCIAL SHEETS</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9323e3cb16af48458579f69c6a9eb28a_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,670,462&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,753,796&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,147,493&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,377,713&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,104,219&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,638,157&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758,332&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199,926&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,680,506&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,969,592&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,880,766&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,656,742&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,256&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,169&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,888,622&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,118,316&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535,556&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028,148&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490,768&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,234,338&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,851,474&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,463,305&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,962,916&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,396,286&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,880&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,779&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,615,995&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,254,381&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,646,791&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,667,446&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease noncurrent liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512,324&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,883,952&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,862,772&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,043,067&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,589,911&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#8212;no par value&#59; 100,000,000 shares authorized&#59; 14,926,059 and  14,988,429 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,688,384&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,121,523&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(735,625)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,131,013)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,952,759&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,990,510&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,352)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,116)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,808,407&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,873,394&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,851,474&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,463,305&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9323e3cb16af48458579f69c6a9eb28a_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,055,483&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,598,177&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,592,642&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928,911&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740,649&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609,982&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157,978&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,244,163&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121,817&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,909,157&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573,082&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360,398&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421,502&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617,765&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,144,057&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097,130&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,190,764&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,327,639&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227,048&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171,218&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,485&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,340,132&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,167,524&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,491,212&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,179,139&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,352,671&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,355,874&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435,729)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,580,962)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,760,029)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,426,963)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,661&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,017&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,549&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,859)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,455)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,276)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,520)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations before income taxes</font></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,143&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,671,756)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,852&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,520,934)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,459)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,455)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,917)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,695)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</font></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,684&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,679,211)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,935&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562,629)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,807&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,622&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,895&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,491&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940,589)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368,152&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,005,734)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (income) loss at subsidiary attributable to noncontrolling interests</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,314&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,236&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,839&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,560&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918,275)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395,388&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,973,895)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - basic</font></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - basic</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Continuing operations - diluted</font></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- Discontinued operations - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- basic</font></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,976,034&#160;</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,463&#160;</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,970,241&#160;</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,020&#160;</font></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">- diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,109,246&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,463&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,171,589&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,020&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9323e3cb16af48458579f69c6a9eb28a_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368,152&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,005,734)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,895&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income(loss) from continuing operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,935&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562,629)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,455,576&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,669&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,923&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,110)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(645,571)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in cash surrender value of life insurance policies over premiums paid</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226,897)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,116&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,666&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,973&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,187,140)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230,220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,421)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,309,914&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158,916&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,987&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,534&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,008,323)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413,768&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526,189)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(869,644)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities from continuing operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490,553&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,332,634&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371,437&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,484,770&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,704,071&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,531)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,883)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable investment funding</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,000)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangibles</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,323)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(722,131)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) investing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366,854)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773,014)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,500,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on line of credit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,000,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,000,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,423,586)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260,735)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of subsidiary shares to noncontrolling interest</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777,664)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,209,220)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,201,250)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,769,955)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,666&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838,898)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,753,796&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,212,635&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,670,462&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,373,737&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9323e3cb16af48458579f69c6a9eb28a_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Unaudited)</font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30, 2020</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,560&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918,275)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Net (income) loss at subsidiary attributable to noncontrolling interests</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,314&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,491&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940,589)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498,807&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,622&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,684&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,679,211)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to net income (loss) from continuing operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,459&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,455&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227,969&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182,607&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,954&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,349&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of debt </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,187,140)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,591)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,661)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,859&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,455&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Earnings (loss) from continuing operations and Adjusted Diluted Earnings (loss) from continuing operations Per Share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,806)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,006)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,976,034&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,463&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.203%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings impact</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share impact</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395,388&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,973,895)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Net (income) loss at subsidiary attributable to noncontrolling interests</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,236&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,839&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368,152&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,005,734)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994,217&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,895&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,935&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,562,629)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to net income (loss) from continuing operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,917&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,695&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,455,576&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334,669&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,923&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of debt </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,187,140)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,017)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,549)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,276&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,520&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Earnings (loss) from continuing operations and Adjusted Diluted Earnings (loss) from continuing operations Per Share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,461&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549,371)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,171,589&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,241,020&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company provided the above adjusted supplemental financial performance measures, which are considered &#34;non-GAAP&#34; financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles (&#34;GAAP&#34;). The definition of these supplemental measures may differ from similarly titled measures used by others.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance.  In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities.  Certain of these items are not settled through cash payments and include&#58; depreciation, amortization, share-based compensation expense and income taxes.  Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes.  In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company defines these supplemental financial measures as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Adjusted Earnings (loss)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">net income (loss) adjusted for the impact of discontinued operations, income taxes, depreciation and amortization expense, share-based compensation and interest income and interest expense.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) Represents the share-based compensation of Cumberland.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) Represents the forgiveness of the PPP Loan by the Small Business Administration.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Adjusted Diluted Earnings (loss) Per Share&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlandpharmaimageaa06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cumberlandpharmaimageaa06.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #3 Z # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD+W5_J%T\\\S8ZM(Y+,?J:^CRWA2=:HI8F24>J6K?EY?(\[&8[V5-N!]M_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (N_$74?$)D!9]*A'V+2U_V1:Q-F1?:=Y>]<]\.3^[C4# "@!1T Q7I.L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $9E1=S' '>O'_VQ
M_P!K[P'^R1\-F\6Z^POM7O\ =;^'/#\4NV74;D#.,X.R-00SR$85?5BJGT#X
MJ_$KP9\(?AUK7Q,\?ZU%8:1H5A)>:A<R'[L:#. .K,> JCEB0!R17X@_'?\
M:<\9_M<?&^_^,/B^22&&4_9]"TDR933+%6.R$8XW'[\C?Q.QYVA0/9RC*Y9A
M4<Y:0COY^1S5ZWL].IZ-J7Q1\??&_P"(5U\4OBCKIU'6;[Y-ZJ4AM8 Q*V\"
M9/EQ+Z=6.68LQS7K?P[^Y%]17@OP\!;R\#/3I7MG@CQ-H>GWD.D2WRRWSX,6
MFVL;SW4O^Y!$#(__  %37TN,IPIQ2222V78RIW>Y]&_#G[D?T%>DZS_R /\
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MCSZ^:9?A:GLZM1*78_86BOQW'_!W?\*/^C*O$'_A80?_ "/1_P 1=_PHZ?\
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M^W5I_P 4VM? ?Q:6#3?$3A8[2_BPEKJ3=, '_52G^X20W\)_A'TDC;U#8Q0
MM%%% !39N87&<?*>:=2/]P_2FE=AL?S!_P#!PG\2M9^(G_!5;XAV.I:@\UOX
M833]'TU=^5ABCLXI651V_>32$^Y->H_\$SO^#?.'_@H=^RMIO[2LG[4[>%#J
M&IWMG_9 \'_; GD2F/=YGVJ/.<9^Z,5X%_P6]_Y2L?&G_L:$_P#26"OVI_X-
MG?\ E%3X:_[&C6?_ $J:OU3,L;B<JX:H3PLN5M16R>ZOU\T?GV7X:CC\_KPQ
M"YDN9]>]NGJ?*O\ Q"&VAY/[>3?^&[_^[J/^(0VT_P"C\V_\-V/_ ).K]JJ*
M^+7%6??\_O\ R6/^1]/_ *O9/_SZ7WO_ #/Q5/\ P:'6@&/^&\G/T^'?_P!W
M5^8G_!1#]CQ?V#OVL?$7[,:>/CXF_L&&T?\ M@Z=]E\[SK>.;'E;WVXWX^\>
ME?URG)! ]*_-?]OW_@W0\&?MY?M2^(/VG-:_:FU3PW<:]':HVD6WA>.Y2'R8
M$AR)#.A.=F>G&:]G(^+<1'%O^T*ON6[+?I\*N>7FO#E"6&7U.FE._=[?-FY_
MP;*?$[6_B#_P3+T[0M=O7G?PIXJU'2;1I&)*V^8[A$Y[*;AE'H !7Z&5\V?\
M$O\ _@G9H_\ P31^ M]\"M#^*%UXLAO?$,^JG4KO35M65I(XD\O8KOD#RASG
MO7TG7R>9UJ&(S"K5H_#)MKYGT>7TZM+!TX5?B22?J?EQ_P '7_\ R8=X0_[*
M9;?^D=S7YR?\&V'_ "EE\%?]@#7/_3=/7Z-_\'7_ /R8=X0_[*9;?^D=S7YR
M?\&V'_*67P5_V -<_P#3=/7WV4_\D96])GQ^:?\ )34/^W/S/Z8J***_,S[L
M*\2_X*2?\F ?&[_LD^O?^D$]>VUXE_P4D_Y, ^-W_9)]>_\ 2">NC"?[W3_Q
M+\S*O_!EZ,_DCT#_ )#EG_U]Q_\ H8K^TA/N#Z5_%OH'_(<L_P#K[C_]#%?V
MD)]P?2ONN/?CP_\ V]_[:?&\'?PZO_;OZBU^5/\ P=F<_L6^ /\ LI2?^D-S
M7ZK5^5/_  =F<?L6^ /^RE)_Z0W-?,<.:YY0_P 7Z,^BSO\ Y%57T9^#/@OQ
M-XP^'OB/3?B/X+U.[TW4='U*.XTS5;1BC6US&0Z,K#HP(SCVK^H__@D+_P %
M%O#7_!1O]EZS^(LTUM;^,M#$>G^.M(A('D7H7(F1<Y$4P!=?0[EY*&OQ'_X)
M5?L$W?\ P4%_8R_:4^&_A:-&\7>&;GPKKG@S>0HDNT365DMRW\(EC^3/3<$/
M:O)O^":G[<WQ(_X)D_M=6GQ%FL;U=+^U'1_'_AJ8%'GL]^)5*' $T3KN0G!#
M(5R QS^@9[@J&>TJM*G;VU%Z=VFD[>C_ #/C<GQ53*94ZD[NE4W\FG:_R_(_
MJ^HKG?A3\3_!/QD^'NB_$WX<:Y#J>A:[IL5[I6H6[@I/!(@96&.G!Y'8@@\B
MN@D<1(7/0=:_)91G"7+)69^C)IJZ"3 4[NA'-?S;_P#!P/\ \%*I?VUOVEU^
M!OPJUQ[GX??#R\DM+)[5]T>KZG_JY[KC[ZJ1Y49YX#L/OU^F/_!PM_P4Q7]C
MO]F\? [X7ZT8/B)\1[*:UMW@D_>:5IG*3W?'*NV6BC/KO8?<K\CO^"0_[ _B
M7]J?QMXO^/&MZ4X\$_"KPM?ZO?WDL?R7>I)9RO9VJYX8B11*WHL>#]\&ON>%
M\#1PE"69XG1+2/KM=>?1'RF?8NIB:\<!0W>LK=NS_-_(^7/@H#_PN+PF3G_D
M9;#K_P!?"5_97%_JE^E?QJ_!48^,?A/'3_A);#_THCK^RJ+_ %2_2MN/%^]P
M_I+]#'A'^!5_Q+\F.K\C_P#@[C_Y-I^$O_8^77_I$]?KA7Y'_P#!W'_R;1\)
M?^Q\NO\ TB>OG.&?^1[0]7^3/;S[_D4U?3]4?E-_P2[_ &%++_@HI^U/;_LX
M7WQ(F\+1S:%>:C_:L.FBZ8>0$.SRRZ==W7/&*_2@?\&BGAD\C]N"^'L? \?_
M ,EU\K_\&QK;/^"HU@<9_P"*%U?_ -!BK^D-+E @&5X'<G_"OI^*\[S3+LS5
M+#SY8\J>R>_J>!D&5Y=C<N]I7A>3;_#T/QD_XA$_#/3_ (;AO?\ PB(__DNE
M_P"(17PRO7]MZ^/L/!$?_P EU^S?VI/[R_F?\*0W<8ZLOY__ %J^9_UKS[K6
M_P#)8_Y'M?ZOY+_SZ7WO_,_F!_X*T?\ !'/QQ_P2[?PMXAE^*UKXR\-^*Y9[
M>TU"/2C93VUS$JNT4D7F2 AE;*L&_A8$#C/MO_!JE\0O$>@?M[>)_ %G>R?V
M9K_PZN9;VU+'89H+JV:*7']Y0\J@^DAKZ2_X.XO$^A/\&?@]X5_M*(:B_BG4
M;I++>/,,*VR*SXZX#,HSZFOE7_@UJTW4+K_@I#J=];6<CPV?PUU%[F0+Q&&N
M;1!GTRS*!]:^V6,KYCP?4JXK65GK;?6R/FUAJ."XGA3H*T;K3Y']%L8P@&,?
MA2O]P_2DAYCZ=S_.E?[A^E?E4%96/OWL?QV?M9_\G4_$S_LH.L_^ETU?H_\
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M3YI=HV0ZCX!>-2?0O'>N1^"FOW HKXR/%F?Q=_;?A'_(^H?#N3O_ )=?B_\
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MU3#8I>_#X?/R^6_H><_%CQY^T;_P5\_;Z?4],TV2^\3^/]<2QT#2O-8PZ79
MXBBS_!%#'EW;'9VZDU_1!\.?V+_AU^P9_P $T?$_[._P\MHY(],^'FKR:KJO
ME!9-4OGLI#/<OWRS= ?NJJJ.%%?*_P#P;>_\$OI/V=OA"/VS/C!X9$7C/QS9
MA?#EM<Q8DTG1VY#8/*R3\,>A$:QC^)A7Z'_M7?\ )LGQ$_[$/6/_ $CDKR>(
M<UA7Q4,%AM*5-VTZM?Y;'I9-ELZ%*6*K:U*FOHGT/Y%/@K_R6/PG_P!C+8_^
ME"5_95%_JE^E?QJ?!3_DL?A+_L9;#_TI2O[*XO\ 5+]*]#C[^/0])?H<'"'\
M"M_B7Y,=7Y'_ /!W'_R;1\)?^Q\NO_2)Z_7"OR/_ .#N/_DVGX2_]CY=?^D3
MU\WPS_R/:'J_R9[F??\ (IJ^GZH_#3P/X_\ 'GPVUT>)?AOXVU?P_J2Q-&NH
M:+J4MK.$;&Y=\3*V#QD9YQ78?\-D_M>*?^3I_B-Q_P!3M?\ _P =KZV_X-J/
M#V@>*O\ @IQ8Z5XFT.SU&U;P1J[&VOK998RP$6#M8$9&:_HLB^"?P;,:D_"?
MPV25&?\ B1P?_$5][GO$5#*L?[&5!3T3OIL^FJ?8^0RC):^/P:JTZSBKM6UZ
M>C1_([_PV5^UYG/_  U/\1O_  M[_P#^.T?\-D_M>L>/VIOB-[ >-[__ ..U
M_7)_PI+X-?\ 1)O#7_@C@_\ B*/^%)?!K&/^%3>&O_!';_\ Q%>-_KKA?^@1
M?>O_ )$]/_5C&?\ 00_Q_P S^/?5_&_B;XJ^,K35/C/\3]<U#S)%CNM9U2XE
MU&XABSR0)9 S 9)QN%?T0?\ !O?^RA^P_P#!W]GZ^^+_ .RY\84^(FN^)0EO
MXJ\27%E]EGLFCPXL?LS9>W52=Q#$ESA@2-N/G'_@ZG_9'^!G@7X0?#[]H[X?
M?#32="U^?Q5)HFKWFCV26_V^&2V>:/S0@ D9# =K$$@,PSC%?.7_  :Y_&OQ
M9X'_ ."A5Y\([#5IAHWC?P=>I?66<QM<6VV>&;'0.JK*H/I(1Z5Z&9UO[;X9
MEB:%Z:5VX]&ET_5?B<N!A_9.>K#U;3<K6EK=7]?Z_(_HJ  & ,?2D?[A^E-@
M=GC#.>2,TY_N'Z5^7+<^\>Q_'9^UG_R=3\3/^R@ZS_Z735;\+?ME?M@>!_#U
MGX1\%_M4_$?2-*TZ!8;#2]+\;W]O;VT0Z)'''*%11V  %5/VL_\ DZCXF?\
M90-9_P#2Z:OZ3?\ @D9\ /@1XE_X)K_!?7/$?P6\)W][=> K*2YN[WP[;2RS
M.5Y9F9"6/N:_9,VS6CE.74:E6GSJ22MIVWU/S#+,NK9CC*D:=3D:UZZZ^31_
M.9_PWI^W-_T>9\5?_#@ZE_\ 'JTO!O[=O[<5SXNTJVG_ &Q_BFZ2:E K(_Q!
MU$A@9%&#F:OZL/\ AF/]FW_HWWP3_P"$K:?_ !NA?V9?V<$8/'\ /!2LI!5E
M\+6@(/J"(^*^;EQC@'%KZHOO7^1] N&<6I:XA_C_ )G5^'G:31X'8DDQ*<D]
M?E%7:;##%;QB*% JCH!3J^ ;N[GV 5XQ_P %'O\ E'G\=_\ LC?B?_TU7->S
MUXQ_P4>_Y1Y_'?\ [(WXG_\ 35<UOA?]ZI_XE^9AB?\ =I^C_(_D8TZ[%A?V
M]\4W>3,LFW.,X;./TK]HK3_@[CL;2V2W/[%5RQ50-W_";JO08_Y]3Z5^+^E6
ML5]J=M93DA)IU1RO4 M@XK]X;+_@TQ_9*N[1)V_:9^(H+*"0(+' R <?ZBOU
MKB&>0QC2_M%-O7EM?Y[/T/SG(XYQ*,W@6DKJ][>=M_F<'_Q%VV/_ $9-<_\
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MOSS6VI]B_A/Y$_\ @HM_R?[\:O\ LJFO?^E\U?T4?\$ /^40_P '/^O#5?\
MT\7U?SK_ /!1;_D_WXU?]E4U[_TOFK^BC_@@!_RB'^#G_7AJO_IXOJ_2^+?^
M1%A_6/\ Z2?#</?\CFO_ -O?^E(^QJ***_-3[H**** "@G%%8_COQEH/P_\
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M793_ $?Z/Y'G\+Y@H.6#D]-7']5^OWGZ&44B,'7<K9![BEK\YZ'VCV/Y@O\
M@X9_Y2S?$O\ ZY:5_P"FZWK]F?\ @W/C1_\ @D7\,-Z XN=>ZC_J-WU?C+_P
M<,_\I9OB7_UQTK_TW6]?LY_P;F_\HBOAC_U\Z[_Z>[ZOT/B&_P#JIA/^W?\
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MTKP'QY^Q_P"-OAB\FM>!+F;Q)I2_,]L8P+^!?]U %G '9 K^BL>:^LJ",C%
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MEF%]@J#EK>^JW^3/ZS/^&C/V>^G_  O;P;_X5%I_\<I)/VC?V?51F'QU\&Y
M)Q_PD]I_\<K^33_AA+]MG_HT?XD?^$7??_&J/^&$OVV>W[(_Q(_\(N^_^-5Y
M*X,P+?\ O:^Y?_)'H_ZS8[_H&?WO_(_57_@Z9_;,^!/Q+^$G@']F_P"&7Q2T
M3Q#KEIXKEUK6(-"U**Z6QACMI(8Q*T;$([F9L*3G"$D 8S\F_P#!M5:74_\
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M2>!6=7@_!4Z4I+%IV3>R_P#DC2EQ)C:E6,7AFKM+K_D?U8@Y/\J\9_X*/?\
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MQ)UJXL;VT\(WDL4\3WLK(Z.L9#*0001U%>2_\,*_MM;=O_#(_P 2/_"+OO\
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MYT6[V>_ET9]AAZRQ-"-2UN9?CV/Y@O\ @X9_Y2S?$O\ ZXZ5_P"FZWK]G/\
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M1E Z!P#B0>S BO0_!O\ P5:^./@-%L_B#X;TKQ3;H &E_P"/.Y(]2Z*T9/\
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MCN)L3.=HHV+G(4?E2T4;B=Q-HZD"D,:\X49/?%.HH!:"*BIT4#Z"EHHHLEL
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M=5O4BFU24.B&.!3S(VZ6,8'=U]:] C8L@8CK7Y/_ /!>[_E(K^Q%_P!C_/\
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M>R7=O9'Z$_ O]H[X'?M)^%Y_&WP)^+&@^+=(M[LVLNH:%J"3QQSJ 6C8J>&
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M=*\3Z!<RR10:OHUTL\$DD;%74.O!(((/H:ZVO@+_ (-H?^44WA;_ +&;6?\
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MPDZR5VD?JO:S-.I<].V1BDU"[CL;1[R:542-2TCMT4 9)HLO]6?]XU0\<?\
M(H:G_P!>,O\ Z :XDKRL=*E>"?D<O\"?VE_@;^TMI%]X@^!'Q7T/Q;8Z9?FR
MU&[T*^6>.WN H;RF9<@-M*G'O7>U^5G_  :F?\FO?%;_ +*M+_Z16]?JG7;F
M>#C@,?4P\7=1MK\D_P!3GP6(EBL+&JU:Z"O&_C3^WS^QY^SEXS'P^^._[2OA
M'PIK36<=VNF:WJ\=O,87)"2;7Y*DJPSZJ:]DKR;XN_L+?L@_'[Q>?'WQO_9S
M\'^*]:^R);#4]=T.*XF6%"Q2,,X)V@LV![FN:@L-[7]_?E\K7_$UK>VY/W5K
M^=[?@<1_P]U_X)H?]'P?#K_PI8:&_P""NG_!-/H/VX?AT#GOXDA-?GG_ ,')
MW[&/[*?[.G[*/@+Q1\"?V??"7A/4+WXHV]E>7N@Z'#;23V[6%[(8F90"5W(I
MQZJ*_0GP;_P2Q_X)T7?A#2KJ\_8M^'$DLFG0-)(_A:W9F)1<DDJ>:]FI@\DI
MX2%=\_OW5O=Z6_S/-IXC'SQ<Z/N^[;^;K?\ R/9_@O\ &_X4?M#>!(?B9\%O
MB!I?B?0+BXEAM]7T:Z$T$CQMM=0Z\$A@0?<5UE<O\(/@M\*_@%X+C^'/P:\!
M:5X:T*&XDF@TG1;);>WC>0Y=E11@%CR?<UU%>)/V?._9WY>E]_P/5CS<JYMP
MK@;7]ISX#7GQXG_9FM_B]H+^/;:T-U/X06^7[>D'EB02&+J!L96SZ$&N^K\G
M?!G_ "M?^)_^R<+_ .F:UKLP.$CB_:W=N2#E]UM/Q.;%8F6'=.ROS24?O/UB
MHHHK@.L*HZ_XCT+PSI$^O:_KEGI]E:(9+J\O;E(HH4'5F9B H]R13/%/B72O
M!_A^\\3:]>);V.GV<MS>W$IPL44:%G<GL  3]!7XV_!O1OC;_P '%_[3GB?Q
MS\5/'&L^&/V9_ 6M?9=(\)Z1<FW;6IAAD61OXI"A621R#Y:R*B $EJ[\!@5B
MXSJU)<M.'Q2_))=6SCQ.+]A)0C'FG+9=^[;Z)'WQ\0/^"U__  3 ^&>KR:'X
MC_;)\)SW,3['_L:2748P>_[RTCD0_@:[3]GW_@I9^PU^U'J\?A_X(?M0^$=9
MU.3'E:/_ &B+>\E_W()]DC_@IQWI_P )?^":W[!_P8\-0^&OAW^RCX%M+>*,
M)YMUX<@NKB0#N\TZO*Y/<LQ->1_M@?\ !";]@G]JJUBU+1?A_'\-_%-M=1S6
MOBKX?V\5A.NU@6#1*OE29&<,5W*<$-V.ZCD<GRWJ1_O.S7_@*7ZLSE_:<%S6
M@_+5/[]?R/L]9(W^XX..N#2USWPK^'UM\+/A_I'P^M/$NL:Q'H^FPV::IX@O
MC<WMTL:[1)/*0#)(>I; R>U=#7E-)2:1WIW284$@#)-%9'C_ ,;>%_AOX(U?
MQ_XTUJ#3M(T339[[5+^Y;$=O;Q1L\CL?0*I/X413E))#T6YQOQA_:Y_9L^ W
MC'1/ 'Q>^.OA?PUK7B,@:'I6L:K'#/>DN(QL5B"078*#W/%>CI)')PDBMCK@
MYK\&_#G['?Q9_P""\T_Q\_X*"Z[<:CIT=I$VD? ;3&F\M6DM'\U4;GD>6HC8
MC@S74C?\LZ_1/_@AK^WK>?ML_LBV^D_$.\9?B'\/&30/&MM=<7$DD0*PW3J>
M09%4[N!^\23VKVL?E$,+A?:4Y\TH-*HOY6U=?+IZGE83,7B:_+*-HRUB^]M_
M\_0^TZ***\0]41CA21Z=ZX#XC?M._ ?X2>/_  _\*/B3\7M!T3Q+XK<1^&]&
MU*^6*XU*3>$VPH>7.\A>.Y KOY/]6W^Z:_)G_@M#_P ID/V-O^P_'_Z=(*[\
MLP<<?BG2D[)*3^Z-SCQV)EA*'M$KZI?>TOU/UF7.T9ZXYI:**X#L"BB@]* ,
MKQ?XT\*> ] N?%GC/Q1I^D:581&2_P!2U.]C@@MT'5GD<A5 ]20*^6O$G_!<
MW_@E?X7UU_#VH_MC>')9TD*&33[:ZNX,Y_YZPPLA^H;%?%O_  <5^.K_ ,3?
MMD_L]_LN?&'QMJ'A_P"#7B"\M[WQ7<P7+0PSN;X0RF1^G[J':1G.SSRWO7Z-
M?"O]@/\ 8*\)_#73_#'P\_9B^'CZ%+8(+=U\-6ET+J)D&'::1':;<#G>6).<
MYKVOJ6"PV#I5\1S-U$VE%I)).VK:>OE8\SZUB<1B)TZ%ER63O>[;5]DUH=A\
M /VI_P!G?]J+PT?%?[/OQK\-^+[*-MMP^AZI',]NW998P=\1QCAP#WZ&O0J^
M</V=O^"4?[%/[*O[16M?M-_ KX9R:#X@UJT^S-9VNH2K86:$?O/(M@=B;S@G
M.X#'RA<G/T>#FO,Q"PJJ?[.VX^=K_AOZG=1=5T_WJ2EY?GJ%%%%8&H4444 %
M%%% !1110 4444 )(BRH8W&0PP017SY\?_\ @F+^R9^T#)/JNJ^!?[ UB<EF
MU?PVRVTC.?XG3!CD)[DKGWKZ$HH _+OXN_\ !#WXS>%99;[X-_$G2?$MKRR6
MFIH;&Y ],Y>-S[EE^@KY]\=?L9?M2_"EI/\ A-?@;XA@BC/S75M8-<PD>HDA
MW+^9%?N-@'J*0JIZJ/RH _ **WFMI3!<0R1R*Q#1NA#+]1VK2M^1@$'CM7[J
M>)/AWX \9(8_%_@?1]54C!&HZ;%/D?\  U-<1K/[%W[*&N2>9??L\>$<]OL^
MBQ0_^BU6@#X;_P""/[^7^TOJ1(Z>$+G.>/\ EO;U^ESW:KCY"2>U?D#_ ,'&
M6AP?L0_#OX7^,OV0]1U/X<:IK?B*_L]5U#P=J]Q8RW4 MT<1.T<@)7< <=,@
M5^</@C]L_P#:_P!>?&M?M6_$RY$@ D67QWJ!#?4>=BOJ,MX6KYE@5B5423OI
M9WT9X]?.*5#&/#N+NNOJKG]3?VV(#+<?4U4O_%6@Z7;M=ZEJ=O;QIR\D]PB*
MH]<DU_.!X5^*GQ3\2;6\3?$[Q'J.[AOM^NW,V>G7?(<]!7K'P^T71]4NDN=2
MTBVN'SGS)X%=L_4BM9\*.C\57\/^"=4,8JBND?MGK_[7'[,GAF0P:Q\>/"<<
MH.#"FO6[R?3:CDY]L5D+^VK\&]4(3P39>)?$;G[@T?PS<[&^DLR1QX]]V/>O
MS\^#UM;VIBBM8$C5< +&@4#\J^I_@YR\)/\ =_I7E8K 4,)KK+YV.F,Y25SO
M/&/[67Q*@MVF\)_ -K? .'\5^(8;=@?[WEVJW&0/0LN?45X%\5_VF?VG=?@D
MMKKXJ0:) P/[CPEI2VS ?W3-,TTAQTW(8_H*];^*8&^08'>OG?XD?ZR7ZFM<
MOITI->ZONO\ F34V/G[XEVQO=9G\1:M=7-_J,X(GU+4KR2YN''7!ED8L1[9P
M.U>)>/94A6224D*,DG'^<U[A\2)$C21W=5 5B69L #'K7O/_  3._P""?,OQ
M,\2:?^U+\:/#S)H.GW*S^#]%O8\'49E(9;Z1#_RQ4\Q*?OL-Y&T(6^K>,H8#
M#.K-V2V7=]CCE3E4GH>U_P#!(K]B.Y_9D^"\_P 0?'VE&W\:^-1#<ZG!,GSZ
M=9J";>S/HPWL[C^^^.=@-?7ZC  )[4B1HA.Q /H*=7Y]B<34QE>5:;UD>A3@
MJ<%%!1116*W+.2^.O_)&_%O_ &+5[_Z3R5^)7_!"/]@?]I/]J+]DO6O'OP@_
MX*.^/_A%IUKXUN;.7P[X5M?,MYY5M[=C<,?/C^<APIXZ(*_;KXRV-[JOPK\2
MZ3IMH\]S=:!=Q6\,8RTDC0NJJ/<D@5\.?\&W7[/?QQ_9J_8G\0^!/CY\*]:\
M):Q<>/[J\@TW7+,P2R0-;6RK( >JED89]J]W+<7+"9-7<&N9RAO9][Z.]_N/
M(Q>']MF-%M:6EU:_EZJQGZG_ ,&]MM\9M5L[C]M#_@H;\8_BQI]G.LJ:-J>J
M_9[9B#TVL\I4')'RE2 3@CK7WI\&?@]\.?@!\+]&^#GPE\*6FA^'= M/LVEZ
M78IMCA3<6/7DDLS,S')9F))))-=,O(!I:\W$X_&8N*A5FW%;+9+Y+0[J&$P^
M'DW".KW>[^]A111GG%<9TVN?D#_P<>^#;SXB_MF?L@^ ;#Q9?Z#/K?B>_L8=
M:TJ39<V#2WVDH)XF[2(3N4^H%>[I_P $._C R@C_ (*__M&#T'_"2G_XNN:_
MX+._LY_'GXU?MU_LE^./A+\(M=\0Z/X,\9RW?BG4M+L&EATR$W^F2!Y6'"C9
M%(WT0U^E-NP:%6!ZBOH\1F-;#97A8T)+:5]$]>=]T[:'B4<#2K8[$3JQ?Q1M
MJU]A=F?FS\8_^"*WQ;\,?"'Q5XEN/^"M/[0FH)IWAR^N7L+SQ$6BN1';NQC<
M;N5;&TCT)I/^#5L@_P#!-356 P&^*>J<>G^B6-??WQZTK4==^!GC31-'LI+F
M[O/">HP6MM$N6ED>VD544=R20!]:^,/^#<7X _&O]F[]@34?AY\>OAAK/A+7
M'^(NHWB:7KEF8)F@>VM%60*W.TE' /\ LFH>/K8K)JL:TDWS0MLOYNU@6%IX
M;-J;IIV<97W?\O=GWW1117SY[9YU^U/^T?\ #_\ 92^ ?BSX]_$RZ\G2/"^C
MRW<RA@'N) O[N!,]7D<K&H_O,.G6OQ:_X)&_\%!?V*_#/[2GQ0_X*(?M^?'R
MUT_XG>,M5>U\/:2VCWES_9=@0K.R-%$ZJ"!% @!R$@/]^OJK_@MG\&_VQOV_
MOVD?AM^P=\)/A3XFL?A:^KVNH>/_ !Z;)UTYG))V^8?E<00AF Z-+(J]5X^\
MOA]^QY^S%\/O!6F>!=$^ 7A 66D6,-G:"?PY:R/Y<4:HI9V0EFPO+$Y)Y-?1
M8>I@\NRRU2\IUM^5I.,4]$WK\3W7:QXM:.)Q>.O"RC3VNG9R:WZ;(_,?_@LQ
M_P %"_\ @D[_ ,%!_P!CS4/ O@[]IFT/CCPW/_:_@>X/A^_0F[08:W+M  JR
MH2F20 VPG[M?5O\ P0I_X*!I^W;^QWIP\7ZLL_COP/''HWBX2/\ O+DHN(+P
MCOYT8!+?\]%D%?4;?LU_LZ-PWP"\%?\ A+6G_P ;K\T?$G[*'[1__!-W_@LI
M;_M'?LC? SQ!X@^#_P 5D,?C[1O"FF-)%I!FD'GMY:#"!)MERF /E:5!@&JI
M5<!C\!+!P3C*/O0<I)Z]8WLK<VZ\R90Q>%QJQ,VFI>[*R?R;U>VWHS]9**CM
M7\R!9"3EE[]:DKYJ]SW'8\F_;M_Y,R^+/_9-=;_](I:_(_\ X(N_\$_/VI_V
MB_V%;?XE?!K_ (*9?$3X6Z<_B+4K>#PGX=M2UFDT93=+D7"'+DC.%XK]>_VS
M- UOQ;^RG\2O"7AC2Y[_ %/5/ .KVFGV%K&6DN)Y+214C4#J2Q  ]Z^9?^#>
M[X'?%W]GO_@GG8_#7XY_#35O"^O1^+=3N7TG6[,PS+%(Z;'VMS@[3BOH,%BY
M83)*W(US<\='9Z6?1GDXG#^WS6GS)VY9;-K73L?GA^RM^S?+^U'^WCXA_8+_
M ."Q_P"TM\5=4\8>'M0\WPCH=[XO<Z3X@1 7^0RAF4O'^\385+(6&59<']T_
MA!\+?A]\$_AIH_PI^%?A*TT+P]H5F+72]*L8]L<$8).!ZDDEB3R22222:^,_
M^"U7_!,C6/VP?AK9?M _L^ Z5\9OAPPO_"6I:>WE7&HQQOYILRXY#@C?$>SY
M' =B/8O^"9W[0?[1GQW_ &<M,G_:Q^!?B/P+X_T7;8^(;76]-:VCU%U7Y;V#
M/!608+*/NON'3!-YKB)9C@X8FG*R6DJ>BY9?S)=5+OT>A. H_5*\J4HW;U4M
MVUV;[J_W'T=2CK^%(/K03@9-?/=3V&NA^37_  <9?\G1?LA_]E+?_P!+=-KH
M_P#@OM^SYXZ^$7B3P#_P5J_9WL3'XP^$NIVR>*%A4_Z;I1DPK2;>653(\+]_
M+G;. E:G_!=;]FWX_?'K]HC]F/Q'\&/A#KWB:Q\*>/6O/$5UI%@TJ:? ;NP<
M22$?=7;&YS_LFOT.^('@7PE\4/A]J_P\\<:)#?:/KNERZ?J=G<("L]O,ACD0
M^Q5B*^DCF$<)A,%46J2FI+NF]5\T>%]4EB:^*B]+\K3\TM']Y\1?M\_\%=/
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M:OC?XQ0R_P#!+?XI>-[;QSXU?4+&\TVV-LB1QR3A3\T;[PPE!!&.GO7U>/\
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M]RBO#Q=#ZKBIT;WL]UJFNC5CU\/6^L48U+6;Z/IW0DG^K;_=-?DS_P %H?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
